Changes in menstrual bleeding can signal other health conditions, including fibroids, ovulation issues, hypothyroidism, polyendocrine metabolic ovarian syndrome (formerly PCOS), endometriosis, pelvic inflammatory disease (PID), bleeding disorders, and endometrial cancer
May 12, 2025 May 19, 2026 Start your weight loss journey with Yazen today Everything you need to do is to create an account and answer some questions about your health More articles Sustainable Weight Loss and Health Benefits in Obesity Care: 18-Month Real-World-Evaluation Results in a Virtual Care Setting from Yazens First Operational Quality follow-up This 18-month real-world evaluation data analysis demonstrates that Yazen Healths fully digital care model, integrating pharmacological treatment and lifestyle intervention can provide effective, sustainable results in a real-world setting
But recent research has surfaced a possible solution: taking a combination of hormone replacement therapy (HRT) and the GLP-1 medication tirzepatide
& Farmer, A
AOD 9604 (Anti-Obesity Drug 9604) is a modified derivative of HGH Fragment 176-191, originally developed by an Australian pharmaceutical company as a candidate compound for obesity research
Tirzepatide 15 mg/week administered to adults with HFpEF, reduced the risk of death from cardiovascular causes or worsening heart failure events resulting in hospitalization, intensification of oral diuresis, or intravenous drugs in urgent care setting by 38% compared to placebo [72]
